- Home
- INTS vs CGTX Comparison
INTS vs CGTX Comparison
Compare INTS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- CGTX
- Stock Information
- Founded
- INTS 2012
- CGTX 2007
- Country
- INTS United States
- CGTX United States
- Employees
- INTS N/A
- CGTX N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- CGTX Health Care
- Exchange
- INTS Nasdaq
- CGTX Nasdaq
- Market Cap
- INTS 10.9M
- CGTX 53.4M
- IPO Year
- INTS 2023
- CGTX 2021
- Fundamental
- Price
- INTS $0.24
- CGTX $1.47
- Analyst Decision
- INTS Strong Buy
- CGTX Strong Buy
- Analyst Count
- INTS 4
- CGTX 3
- Target Price
- INTS $4.50
- CGTX $2.83
- AVG Volume (30 Days)
- INTS 4.2M
- CGTX 8.1M
- Earning Date
- INTS 11-12-2025
- CGTX 11-12-2025
- Dividend Yield
- INTS N/A
- CGTX N/A
- EPS Growth
- INTS N/A
- CGTX N/A
- EPS
- INTS N/A
- CGTX N/A
- Revenue
- INTS N/A
- CGTX N/A
- Revenue This Year
- INTS N/A
- CGTX N/A
- Revenue Next Year
- INTS N/A
- CGTX N/A
- P/E Ratio
- INTS N/A
- CGTX N/A
- Revenue Growth
- INTS N/A
- CGTX N/A
- 52 Week Low
- INTS $0.19
- CGTX $0.22
- 52 Week High
- INTS $4.19
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- INTS 37.27
- CGTX 39.92
- Support Level
- INTS $0.22
- CGTX $1.43
- Resistance Level
- INTS $0.30
- CGTX $2.60
- Average True Range (ATR)
- INTS 0.02
- CGTX 0.31
- MACD
- INTS -0.00
- CGTX -0.19
- Stochastic Oscillator
- INTS 29.21
- CGTX 2.94
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.